MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
1.340
-0.020
-1.47%
After Hours: 1.320 -0.02 -1.49% 16:06 06/17 EDT
OPEN
1.330
PREV CLOSE
1.360
HIGH
1.420
LOW
1.320
VOLUME
255.91K
TURNOVER
0
52 WEEK HIGH
4.890
52 WEEK LOW
1.303
MARKET CAP
65.18M
P/E (TTM)
-1.2572
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CUE last week (0610-0614)?
Weekly Report · 1d ago
Weekly Report: what happened at CUE last week (0603-0607)?
Weekly Report · 06/10 10:56
Cue Biopharma Welcomes Michael J. Fox to Board, Shareholders Vote
TipRanks · 06/07 21:10
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Pharvaris (PHVS) and Cue Biopharma (CUE)
3 analysts just weighed in on OrthoPediatrics, Pharvaris and Cue Biopharma with bullish sentiments. In a report released today, JMP Securities reiterated a Buy rating on the Healthcare sector stocks. The analysts also reiterated their bullish sentiments on the company’s shares.
TipRanks · 06/06 05:31
CUE BIOPHARMA PRESENTS UPDATED DATA FROM PHASE 1 TRIAL OF CUE-101 IN RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER AT THE 2024 ASCO ANNUAL MEETING
Reuters · 06/04 12:00
Weekly Report: what happened at CUE last week (0527-0531)?
Weekly Report · 06/03 10:59
Weekly Report: what happened at CUE last week (0520-0524)?
Weekly Report · 05/27 11:03
Weekly Report: what happened at CUE last week (0513-0517)?
Weekly Report · 05/20 10:57
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.